Position in NVAX
as of Jun 30, 2026
· filed Jul 24, 2026
Position Value
$165,726
+$18,799 QoQ
Shares Held
17,593
-2.5% QoQ
Ownership
0.011%
of shares outstanding
% of Portfolio
0.04%
of 13F equity value
Holder Rank
#140
of 263 holders
Holding Since
Dec 2025
3 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in NVAX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Abel Hall, LLC holds $15,603,659 across 68 Biotechnology names. NVAX ranks #34 (1.1% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | RVMD |
Revolution Medicines, Inc.
|
5,394 | $1,010,188 | |
| 2 | MDGL |
Madrigal Pharmaceuticals, Inc.
|
1,389 | $745,823 | |
| 3 | TGTX |
Tg Therapeutics, Inc.
|
13,570 | $745,535 | |
| 4 | ARWR |
Arrowhead Pharmaceuticals, Inc.
|
8,329 | $678,896 | |
| 5 | KYMR |
Kymera Therapeutics, Inc.
|
4,681 | $536,770 | |
| 6 | PTGX |
Protagonist Therapeutics, Inc
|
4,286 | $525,377 | |
| 7 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,050 | $521,566 | |
| 8 | BBIO |
BridgeBio Pharma, Inc.
|
6,619 | $492,983 |
All Filings in NVAX
Export CSV
3 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $165,726 | 17,593 | Shares | Sole | 2026-07-24 | |
| 2026-03-31 | $146,927 | 18,050 | Shares | Sole | 2026-04-28 | |
| 2025-12-31 | $92,796 | 13,809 | Shares | Sole | 2026-02-17 | |
| No filing history on record for this holder in this stock. | ||||||